skip to main content

Denosumab calcium — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardMusculoskeletal TherapeuticsDenosumab calciumGPhC CRA

A patient with chronic kidney disease starts denosumab for osteoporosis and asks why blood tests are needed. What monitoring is required?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Check calcium and renal-related risk factors, with vitamin D and calcium adequacy

Denosumab can cause hypocalcaemia, especially with renal impairment or vitamin D deficiency. In this scenario, the pharmacist should prioritise safe supply, appropriate counselling and timely referral or clarification where needed. This is the single best answer because the other options would either delay assessment, ignore a clinically significant risk, or create an unsafe legal or professional outcome.

Reference: BNF